{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-021848","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2023-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.492034+00:00","generated_at":"2026-06-13T22:07:08.374147+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"ProPhase Labs stockholders approve equity plan amendments, increase share reserves","bullets":["Amended 2022 Equity Compensation Plan approved, increasing share reserve by 700,000 shares.","Amended 2022 Directors' Equity Compensation Plan approved, increasing share reserve by 150,000 shares.","All four director nominees elected: Ted Karkus, Jason Barr, Louis Gleckel, MD, Warren Hirsch.","Ratification of Morison Cogen LLP as independent auditor for fiscal year 2023 approved (15,066,019 for)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-021848","json":"https://secwatch.observer/filing/0001493152-23-021848.json","markdown":"https://secwatch.observer/filing/0001493152-23-021848.md","text":"https://secwatch.observer/filing/0001493152-23-021848.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315223021848/0001493152-23-021848-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315223021848/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T22:07:08.374147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e5b2560acce6b93363bd2f43a785689098d21a1","claim":"ProPhase Labs, Inc. shareholders approved Ratification of the Appointment of Independent Auditors at the 2023-12-31 meeting.","evidence_excerpt":"The ratification of the appointment by the Audit Committee of the board of directors of Morison Cogen LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was approved by the following vote: For Against Abstain Broker Non- Votes 15,066,019 15,111 7,885 3,035,580","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315223021848/0001493152-23-021848-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-31"}],"fact_type":"shareholder_vote"},{"claim_id":"77229aad87214ff15c6e7369dd4f9ade0c7b34f5","claim":"ProPhase Labs, Inc. shareholders approved Approval of the Amended and Restated 2022 Equity Compensation Plan.","evidence_excerpt":"The Amended 2022 Plan was approved by the following vote: For Against Abstain Broker Non- Votes 11,415,903 619,094 14,438 3,035,580","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315223021848/0001493152-23-021848-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"9e1a76d4440f158d1a5ff5fb63959d8451c67c97","claim":"ProPhase Labs, Inc. shareholders approved Approval of the Amended and Restated 2022 Directors’ Equity Compensation Plan.","evidence_excerpt":"The Amended 2022 Directors’ Plan was approved by the following vote: For Against Abstain Broker Non- Votes 11,040,479 991,383 21,573 3,035,580","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315223021848/0001493152-23-021848-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"c5d1716a0f5124f1d518391b40efb6c46d7a724b","claim":"ProPhase Labs, Inc. shareholders approved Election of Directors.","evidence_excerpt":"Each of the nominees for election to the board of directors was elected to hold office for a one-year term and until their respective successors are elected and qualified by the following votes: Name For Withheld Broker Non- Votes Ted Karkus 12,023,672 29,763 3,035,580 Jason Barr 10,721,866 1,331,569 3,035,580 Louis Gleckel, MD 10,602,209 1,451,226 3,035,580 Warren Hirsch 11,152,966 900,469 3,035,580","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315223021848/0001493152-23-021848-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}